ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2020
FLAME: A computerized neuropsychological composite for trials in early dementia.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
'Oral Microbiome -Dietary Nitrate' Interactions and Cognitive Health in Older Age
A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease (FEAD)
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Cognitive reserve and everyday functioning in cognitively unimpaired older adults: evidence from the CAN-PROTECT study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- A digital intervention to protect cognitive health in older adults with cognitive impairment: a three-arm, open-label, randomised controlled trial.The Lancet. Primary care · 2026Article
- Digital Cognitive Phenotyping for Differential Diagnosis and Monitoring in Neurological Conditions.Annals of clinical and translational neurology · 2026Article
- Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults.Nature communications · 2026Article
- Screening for Alzheimer's disease in the community using an AI-driven screening platform: design of the PREDICTOM study.The journal of prevention of Alzheimer's disease · 2026Article
- Lifetime Exposure to Endogenous Estradiol and Markers of Dementia Risk: Associations with Later Life Cognitive, Behavioral, and Functional Complaints.Diagnostics (Basel, Switzerland) · 2026Article
- Preventing and Treating Insomnia Symptoms in Midlife and Older Adults (ASLEEP): Protocol for a Randomized Controlled Trial Using the PROTECT Norge Infrastructure.JMIR research protocols · 2026Article
- Synuclein Disorder-Related Genetic Determinants of Mild Behavioural Impairment in a Pre-Clinical Community Cohort.International journal of geriatric psychiatry · 2026Article
- Discerning cognitive domains through online assessment in aging participants in Norwegian Cohort 50.Scientific reports · 2025Article
- Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.medRxiv : the preprint server for health sciences · 2025Article
- Web-Based Assessment of Cognition and Dementia Risk Factors in Over 3000 Norwegian Adults Aged 50 Years and Older: Cross-Sectional PROTECT Norge Study.JMIR aging · 2025Article
- Within- and between-individual associations between sleep and cognition in older community-dwelling individuals.Frontiers in aging · 2025Article
- Oral microbiome and nitric oxide biomarkers in older people with mild cognitive impairment andPNAS nexus · 2025Article
- Remote Digital Technologies for the Early Detection and Monitoring of Cognitive Decline in Patients With Type 2 Diabetes: Insights From Studies of Neurodegenerative Diseases.Journal of diabetes science and technology · 2024Review
- Linking cognitive and behavioral reserve: Evidence from the CAN-PROTECT study.Alzheimer's & dementia (New York, N. Y.) · 2024Article
- Online cognitive monitoring technology for people with Parkinson's disease and REM sleep behavioural disorder.NPJ digital medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSensitive neuropsychological tests are needed to improve power for clinical trials in early Alzheimer's disease (AD).
methodsTo develop a neuropsychological composite (FLAME - Factors of Longitudinal Attention, Memory and Executive Function), we assessed, 10,714 participants over the age of 50 from PROTECT with validated computerized assessments for 2 years. A factorial analysis was completed to identify the key cognitive factors in all participants, and further analyses examined sensitivity to change in people with stage 2/3 early Alzheimer's disease (AD) according to the US Food and Drug Administration (FDA) framework.
resultsThe FLAME composite score (speed of attention, accuracy of attention, memory, and executive function) distinguished between normal cognition and stage 2/3 early AD at baseline, and was sensitive to cognitive and global/functional decline over 2 years, with the potential to improve power for clinical trials. DISCUSSION: FLAME is sensitive to change, providing a straightforward approach to reduce sample size for RCTs in early AD.
conclusionFLAME is a useful computerized neuropsychology composite with utility for clinical trials focusing on cognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.